Quantitative Concept – Page 6

LB Pharmaceuticals Raises $285M in Upsized IPO to Fund Late-Stage Schizophrenia Drug Development

2 months ago talkbio0Tagged amisulpride, Approved, Central Nervous System Agents, Depression, Bipolar, IPO, LB-102, Pounds, Schizophrenia, United States Food and Drug Administration

LB Pharmaceuticals; IPO; schizophrenia; LB-102; amisulpride; Phase 3 clinical trial; bipolar depression; biotech fundraising; CNS drugs; FDA approval

LB Pharmaceuticals Files for $228M IPO to Fund Phase III Schizophrenia Drug

2 months ago talkbio0Tagged Alzheimer 's psychosis, amisulpride, Clinical Nurse Specialists, Depression, Bipolar, IPO, LB-102, Nasdaq, Phase 3 Clinical Trials, Pounds, Schizophrenia, United States Food and Drug Administration

LB Pharmaceuticals; IPO; Phase III trial; schizophrenia; LB-102; biotech; CNS therapeutics; bipolar depression; Alzheimer’s psychosis; amisulpride; FDA; Nasdaq

Eli Lilly Touts ‘Striking’ Progression-Free Survival Results for Jaypirca in New Front-Line CLL Study

2 months ago talkbio0Tagged BRUIN, BTK inhibitor, Chronic Lymphocytic Leukemia, Clinical Trials, CLL, CLL-313, eli lilly, expansion, First line treatment, Jaypirca, Labels (device), Progression-Free Survival

Jaypirca; Eli Lilly; CLL; chronic lymphocytic leukemia; BRUIN CLL-313; progression-free survival; BTK inhibitor; first-line treatment; clinical trial; label expansion

Daiichi and Merck’s Lung Cancer ADC Achieves 48% Response Rate in Pivotal Trial

2 months ago talkbio0Tagged Accelerated, Antibody-Drug Conjugates, Approved, Breakthrough Therapy, CD276 gene, Co., Daiichi, Deruxtecan, Frequency of Responses, IDeate-Lung01, Identifier, ifinatamab, Overall Survival, Progression-Free Survival, Sankyo, Small cell carcinoma of lung, therapeutic autologous dendritic cells, United States Food and Drug Administration

Daiichi Sankyo; Merck & Co.; ifinatamab deruxtecan; I-DXd; B7-H3; antibody-drug conjugate; ADC; small cell lung cancer; SCLC; IDeate-Lung01; objective response rate; accelerated approval; progression-free survival; overall survival; FDA Breakthrough Therapy Designation

AstraZeneca Escalates EGFR Lung Cancer Rivalry with J&J: Tagrisso Combo Posts Survival Win

2 months ago talkbio0Tagged AstraZeneca, Combined, EGFR-mutated, FLAURA2 trial, Johnson & Johnson, Lazcluze, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Overall Survival, Pharmacotherapy, Rybrevant, Tagrisso

AstraZeneca; Tagrisso; EGFR-mutated NSCLC; Johnson & Johnson; Rybrevant; Lazcluze; Flaura2 trial; overall survival; lung cancer; chemotherapy combination

BioNTech and DualityBio Achieve Phase 3 Success with ADC Therapy for HER2-Positive Breast Cancer, Advancing Oncology Pipeline

2 months ago talkbio0Tagged Antibody-Drug Conjugates, BioNTech, DualityBio, HER2-positive carcinoma of breast, Market, Oncology Pipeline, pamirtecan, Phase 3 trial, Progression-Free Survival, trastuzumab

BioNTech; DualityBio; antibody-drug conjugate (ADC); HER2-positive breast cancer; trastuzumab pamirtecan; BNT323/DB-1303; phase 3 trial; progression-free survival; oncology pipeline; ADC market

Survival Benefit of Amgen’s Bemarituzumab in Gastric Cancer Attenuates at Final Analysis

2 months ago talkbio0Tagged amgen, Attenuated by (contextual qualifier), bemarituzumab, Benefit, final analysis, FORTITUDE-101, FORTITUDE-102, Malignant neoplasm of stomach, nivolumab, Opdivo, Overall Survival, Zai Lab

Amgen; bemarituzumab; gastric cancer; Phase 3 trial; overall survival; attenuated benefit; final analysis; FORTITUDE-101; FORTITUDE-102; Zai Lab; Opdivo; nivolumab

Treeline Announces $200M Funding Boost, Moves Three Cancer Drugs into Clinic

2 months ago talkbio0Tagged BCL6 gene, cancer drugs, Clinical Trials, Degrader, EZH2 protein, human, Funding, Inhibitor, K-ras Oncogene, Lymphoma, Series, Solid Neoplasm, TLN-121, TLN-254, TLN-372, Treeline

Treeline Biosciences; cancer drugs; clinical trials; TLN-121; TLN-372; TLN-254; BCL6 degrader; KRAS inhibitor; EZH2 inhibitor; Series A funding; lymphoma; solid tumors

Gilead Unveils New Manufacturing Site in California as Part of $32B U.S. Investment Plan

2 months ago talkbio0Tagged Billion, Biological Factors, California, economic impact, expansion, Foster City, Gilead Sciences, Investments, Manufacturing, Manufacturing Facilities, R&D, Surgical construction, United States

Gilead Sciences; Foster City; California; manufacturing facility; biopharmaceuticals; $32 billion investment; economic impact; expansion; R&D; job creation; U.S. manufacturing

UK Pharma Trade Group Calls for Overhaul of Government’s Life Sciences Investment Evaluation and Medicines Pricing Schemes

2 months ago talkbio0Tagged ABPI, Biological Science Disciplines, Evaluation, government review, innovation, Investments, Nance-Horan syndrome, pharma trade group, Pricing, statutory scheme, UK, valproic acid glucuronide

UK life sciences; ABPI; VPAG; pharma trade group; investment evaluation; medicines pricing; government review; NHS; innovation; statutory scheme